| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
Baseline and Changes in Serum B-Cell Maturation Antigen Levels Rapidly Indicate Changes in Clinical Status Among Patients with Relapsed/Refractory Multiple Myeloma Starting New Therapy
|
Bujarski, Sean
|
|
|
16 |
4 |
p. 503-515
|
artikel
|
| 2 |
Bintrafusp Alfa, a Bifunctional Fusion Protein Targeting TGF-β and PD-L1, in Patients with Esophageal Adenocarcinoma: Results from a Phase 1 Cohort
|
Tan, Benjamin
|
|
|
16 |
4 |
p. 435-446
|
artikel
|
| 3 |
Bintrafusp Alfa, a Bifunctional Fusion Protein Targeting TGFβ and PD-L1, in Patients with Esophageal Squamous Cell Carcinoma: Results from a Phase 1 Cohort in Asia
|
Lin, Chia-Chi
|
|
|
16 |
4 |
p. 447-459
|
artikel
|
| 4 |
Cardiovascular Toxicities of Antiangiogenic Tyrosine Kinase Inhibitors: A Retrospective, Pharmacovigilance Study
|
Goldman, Adam
|
|
|
16 |
4 |
p. 471-483
|
artikel
|
| 5 |
Multicenter, Open-Label, Phase I Study of DSP-7888 Dosing Emulsion in Patients with Advanced Malignancies
|
Spira, Alexander
|
|
|
16 |
4 |
p. 461-469
|
artikel
|
| 6 |
Prognostic Impact of Early Treatment Interruption of Nivolumab Plus Ipilimumab Due to Immune-Related Adverse Events as First-Line Therapy for Metastatic Renal Cell Carcinoma: A Multi-Institution Retrospective Study
|
Ishihara, Hiroki
|
|
|
16 |
4 |
p. 493-502
|
artikel
|
| 7 |
Risk and Benefit for Targeted Therapy Agents in Pediatric Phase II Trials in Oncology: A Systematic Review with a Meta-Analysis
|
Strzebonska, Karolina
|
|
|
16 |
4 |
p. 415-424
|
artikel
|
| 8 |
Safety and Efficacy of Neoadjuvant Immune Checkpoint Inhibitor Therapy in Patients with Resectable Non-small-Cell Lung Cancer: A Systematic Review
|
Zhao, Ziran
|
|
|
16 |
4 |
p. 425-434
|
artikel
|
| 9 |
Starting Imatinib at 400 mg Daily in Patients with Gastrointestinal Stromal Tumors Harboring KIT Exon 9 Mutations: A Retrospective, Multicenter Study
|
Callejo, Almudena
|
|
|
16 |
4 |
p. 485-492
|
artikel
|
| 10 |
The Pan-Immune-Inflammation Value in Patients with Metastatic Melanoma Receiving First-Line Therapy
|
Fucà, Giovanni
|
|
|
16 |
4 |
p. 529-536
|
artikel
|
| 11 |
The Role of p53 Expression in Patients with RAS/BRAF Wild-Type Metastatic Colorectal Cancer Receiving Irinotecan and Cetuximab as Later Line Treatment
|
Ziranu, Pina
|
|
|
16 |
4 |
p. 517-527
|
artikel
|
Tijdschrift beschrijving